#PCRX hashtag - Bluesky

Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation Pacira BioSciences (Nasdaq: PCRX) responded to DOMA's nomination of three director candidates and reaffirmed its 5x30 strategy to drive long-term shareholder value. Key 2025 results: 2.5 million patients treated, EXPAREL volume +6.2% YoY, GAAP gross margin 79% (non-GAAP 81%), and $150 million share repurchases reducing shares from 47 to 41 million. The company highlighted expansion of its EXPAREL patent estate to 21 Orange-Book listed patents, progress in Phase 2 programs PCRX-201 and PCRX-2002, and several 2026 clinical milestones including a Phase 3 interim analysis and multiple topline readouts.

2 weeks ago

#PCRX Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation

www.stocktitan.net/news/PCRX/pacira-bio-sci...

0 0 0 0

DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc. {"summary":"","positive":[],"negative":[],"faq":[]}

2 weeks ago

#PCRX DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.

www.stocktitan.net/news/PCRX/doma-perpetual...

0 0 0 0

Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR) Pacira BioSciences (NASDAQ: PCRX) presented real-world IGOR registry data at AAOS 2026 showing benefits for EXPAREL and ioveraº in knee procedures and osteoarthritis pain. For TKA, liposomal bupivacaine (LB, n=42) showed lower acute NRS pain (3.9 vs 4.9; P<0.001), lower BPI-SF at 3 months (2.6 vs 2.9; P=0.03), and shorter hospital stays (15.0 vs 20.6 hours; P=0.007). Cryoneurolysis (n=129) was associated with sustained pain and functional improvements through 12 months (P<0.01) versus typical 4–6 month relief from intra-articular agents.Findings derive from a multicenter, prospective, observational registry (IGOR) and were presented March 2, 2026 at AAOS.

3 weeks ago

#PCRX Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)

www.stocktitan.net/news/PCRX/pacira-bio-sci...

0 0 0 0

Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results Pacira BioSciences (Nasdaq: PCRX) reported Q4 2025 revenue of $196.9M and full-year revenue of $726.4M, led by EXPAREL sales of $155.8M in Q4 and $575.1M for 2025.GAAP net income was $1.6M in Q4 and $7.0M for 2025; adjusted EBITDA was $38.7M in Q4 and $186.5M for the year. The company repurchased 5.9M shares for $150M in 2025 and provided 2026 guidance including EXPAREL sales of $600–$620M.

1 month ago

#PCRX Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results

www.stocktitan.net/news/PCRX/pacira-bio-sci...

0 0 0 0

Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets Pacira (NASDAQ: PCRX) announced an exclusive agreement with LG Chem to commercialize EXPAREL Under the deal, Pacira will manufacture EXPAREL and receive an undisclosed upfront payment, a transfer price, and tiered royalties on future sales; LG Chem will pursue regulatory approvals and plans to file for marketing authorizations in South Korea and Thailand within six months. The partnership is intended to expand patient access to opioid-sparing postsurgical pain control and advance Pacira’s 5x30 strategy.

2 months ago

#PCRX Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets

www.stocktitan.net/news/PCRX/pacira-announc...

0 0 0 0

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid

2 months ago

#PCRX Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

www.stocktitan.net/news/PCRX/pacira-reports...

0 0 0 0

DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc. {"summary":"","positive":[],"negative":[],"faq":[]}

2 months ago

#PCRX DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.

www.stocktitan.net/news/PCRX/doma-perpetual...

0 0 0 0

Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical {"summary":"","positive":[],"negative":[],"faq":[]}

4 months ago

#PCRX Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical

www.stocktitan.net/news/PCRX/pacira-bio-sci...

0 0 0 0

Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance Pacira BioSciences, Inc. (Nasdaq: PCRX), the

4 months ago

#PCRX Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

www.stocktitan.net/news/PCRX/pacira-bio-sci...

0 0 0 0

Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee Pacira BioSciences (Nasdaq: PCRX) announced it has concluded patient enrollment in Part A of the Phase 2 ASCEND study of PCRX-201 for osteoarthritis of the knee. Part A randomized ~45 patients 1:1:1 to two dose levels (1.4×1010 GC and 1.4×1011 GC) or saline, with steroid pretreatment for all cohorts. The study will enroll ~135 patients across Parts A and B; Part B will randomize ~90 patients using commercial-scale manufactured drug product. The primary endpoint is safety through Week 52; secondary endpoints include pain and function at Weeks 38 and 52 (NRS, WOMAC, KOOS). Pacira expects topline Part A results before the end of 2026 and will follow participants for five years.

4 months ago

#PCRX Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

www.stocktitan.net/news/PCRX/pacira-bio-sci...

0 0 0 0

4 months ago

#PCRX Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control

www.stocktitan.net/news/PCRX/pacira-bio-sci...

0 0 0 0

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL® Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients today reported it has received a Paragraph IV Certification Notice Letter (PIV

5 months ago

#PCRX Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

www.stocktitan.net/news/PCRX/pacira-bio-sci...

0 0 0 0

Pacira BioSciences Reports Second Quarter 2025 Financial Results Pacira BioSciences (Nasdaq: PCRX) reported Q2 2025 financial results with total revenues of $181.1 million. Key product sales included EXPAREL at $142.9 million, ZILRETTA at $31.3 million, and iovera° at $5.6 million. The company reported a net loss of $4.8 million ($0.11 per share) and adjusted EBITDA of $54.3 million.Notable developments include surpassing 50% enrollment in the Phase 2 ASCEND study for PCRX-201, securing a new $300 million revolving credit facility, and entering a strategic collaboration with Johnson & Johnson MedTech. The company also received a $28.3 million favorable court ruling payment and strengthened its patent portfolio. Pacira updated its 2025 guidance, narrowing total revenue to $730-750 million and increasing non-GAAP gross margin to 78-80%.The company repurchased 2.0 million shares at an average price of $25.59 per share, totaling $50.0 million.

7 months ago

#PCRX Pacira BioSciences Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/PCRX/pacira-bio-sci...

0 0 0 0

Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts Pacira BioSciences (NASDAQ: PCRX) has announced a strategic collaboration with Johnson & Johnson MedTech to expand the market reach of ZILRETTA, their extended-release treatment for osteoarthritis knee pain. The partnership aims to leverage J&J's specialized early intervention sales force to co-promote the treatment.The collaboration aligns with Pacira's 5x30 strategy and is expected to significantly expand access across the 7 million intra-articular knee injections administered annually in the U.S. The partnership will extend ZILRETTA's reach beyond orthopedic practices into sports medicine, pain management, and rheumatology specialties.

8 months ago

#PCRX Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts

www.stocktitan.net/news/PCRX/pacira-bio-sci...

0 0 0 0

Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025 Pacira BioSciences (NASDAQ: PCRX) premiered a new film at BIO 2025 titled 'The Next Frontier: Mark & Leah's Story,' produced by BBC StoryWorks Commercial Productions. The film chronicles former tennis player Mark Allen's journey from opioid dependency following knee injuries to successful recovery through non-opioid pain management solutions. The story showcases how Mark, with support from his nurse wife Leah, transformed his life using alternative pain therapies, enabling him to open a tennis academy and enjoy time with his grandchildren. The film debuts amid concerning statistics, with CDC reporting 54,743 opioid-related deaths in 2024. Chronic pain affects 82 million Americans and costs the U.S. up to $635 billion annually, exceeding the combined costs of cancer and heart disease, highlighting the urgent need for innovative non-opioid pain management solutions.

9 months ago

#PCRX Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025

www.stocktitan.net/news/PCRX/pacira-bio-sci...

0 0 0 0

Pacira BioSciences Reports First Quarter 2025 Financial Results Pacira BioSciences (PCRX) reported Q1 2025 financial results with total revenues of $168.9 million. Key product sales included EXPAREL at $136.5 million, ZILRETTA at $23.3 million, and iovera° at $5.1 million. The company achieved net income of $4.8 million ($0.10 per share) and adjusted EBITDA of $44.1 million. Notable developments include a favorable EXPAREL patent litigation settlement extending exclusivity to 2039, elimination of EXPAREL royalty obligations to RDF, and headquarters relocation to Brisbane, California. The company maintains its 2025 guidance with total revenue projected at $725-765 million. Pacira also completed the strategic acquisition of GQ Bio and initiated a Phase 2 study for PCRX-201 in knee osteoarthritis treatment. The company announced a $300 million stock buyback program, demonstrating confidence in its long-term growth outlook.

10 months ago

#PCRX Pacira BioSciences Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/PCRX/pacira-bio-sci...

0 0 0 0

Revolutionary Gene Therapy Cuts Knee Osteoarthritis Pain by 65% in Landmark 2-Year Study Results First gene therapy for osteoarthritis achieves 72% stiffness reduction from single injection. FDA RMAT-designated treatment shows promising safety profile. See full data.

11 months ago

#PCRX Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee

www.stocktitan.net/news/PCRX/pacira-bio-sci...

0 0 0 0

DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders Pacira BioSciences (NASDAQ: PCRX) has announced a significant $300 million share repurchase program, receiving support from DOMA Perpetual Capital Management, which owns 4.2% of the company's outstanding shares.The initiative, representing the largest buyback in Pacira's history, comes alongside a new emphasis on increasing pre-tax net income margins. DOMA Perpetual views these moves as reflecting Pacira's strong financial position and the Board's commitment to disciplined capital allocation.According to Pedro Escudero, CEO of DOMA Perpetual, Pacira has entered a period of rapid growth, with scaling earnings and free cash flow enabling capital returns while maintaining investment in growth. DOMA Perpetual believes the stock is currently undervalued relative to both its historical average and future growth potential.

11 months ago

#PCRX DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders

www.stocktitan.net/news/PCRX/doma-perpetual...

0 0 0 0

Pacira Wins Strategic Patent Deal: EXPAREL Maintains Market Dominance Through 2030 Strategic settlement grants Fresenius limited EXPAREL generic rights starting 2030, protecting Pacira's market leadership. Full volume rights delayed until 2039.

11 months ago

#PCRX Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL

www.stocktitan.net/news/PCRX/pacira-bio-sci...

0 0 0 0

Game-Changing Knee Osteoarthritis Gene Therapy Advances After 2-Year Pain Relief Success Revolutionary gene therapy PCRX-201 enters Phase 2 trials following unprecedented 2-year pain relief results in Phase 1. 135 patients to test breakthrough treatment.

11 months ago

#PCRX Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

www.stocktitan.net/news/PCRX/pacira-bio-sci...

0 0 0 0

DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences DOMA Perpetual Capital Management, owning 4.2% of Pacira BioSciences (NASDAQ: PCRX), has nominated three directors to the company's board amid concerns over poor performance and capital allocation. The activist investor highlighted that Pacira's stock has declined 76% over the past decade while the S&P 500 gained 167%.The key concerns include:33% stock price decline under current CEO Frank LeeManagement compensation totaling nearly half a billion dollars (approximately 50% of current market cap)Questionable capital allocation strategiesDOMA's nominated candidates include: Joseph Kromholz (IP law expert), Philip Pucciarelli (healthcare investment banking veteran), and Eric de Armas (DOMA's CFO/CCO). DOMA aims to accelerate share buybacks and return cash to shareholders while avoiding substantial risks until IP battle certainty is achieved.

1 year ago

#PCRX DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences

www.stocktitan.net/news/PCRX/doma-perpetual...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with declining money flow, Wed Mar 12th - #PCRX #THS #ZYXI #WNEB #VANI #TBCH #RGP #QTTB #MRTN #LTRY #KALA #IBCP #HCKT #CTKB #BIRD #AVR #SMP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Pacira BioSciences, Inc. Shareholders Alerted About Class Action Lawsuit and Important Deadline The Gross Law Firm informs Pacira BioSciences shareholders about a class action lawsuit over patent infringement. Register now to participate.

1 year ago

Pacira BioSciences, Inc. Shareholders Alerted About Class Action Lawsuit and Important Deadline #United_States #New_York #Gross_Law_Firm #Pacira_BioSciences #PCRX

0 0 0 0

Pacira BioSciences Securities Fraud Lawsuit Deadline Approaches: Investors Can Lead the Charge Investors in Pacira BioSciences, Inc. have a crucial opportunity to join a securities fraud lawsuit. The deadline to act is March 14, 2025.

1 year ago

Pacira BioSciences Securities Fraud Lawsuit Deadline Approaches: Investors Can Lead the Charge #United_States #New_York #Rosen_Law_Firm #Pacira_BioSciences #PCRX

0 0 0 0

Levi & Korsinsky Informs Pacira BioSciences Shareholders About Class Action Lawsuit and Deadline Levi & Korsinsky announces important details regarding a class action lawsuit against Pacira BioSciences, including critical deadlines for shareholders.

1 year ago

Levi & Korsinsky Informs Pacira BioSciences Shareholders About Class Action Lawsuit and Deadline #USA #New_York #Levi_&_Korsinsky #Pacira_BioSciences #PCRX

0 0 0 0

Pacira BioSciences Shareholders Face Urgent Lead Plaintiff Deadline in Lawsuit The Gross Law Firm alerts Pacira shareholders of the March 14, 2025 lead plaintiff deadline in a significant lawsuit regarding patent invalidation. Immediate action is required.

1 year ago

Pacira BioSciences Shareholders Face Urgent Lead Plaintiff Deadline in Lawsuit #United_States #New_York #Gross_Law_Firm #Pacira_BioSciences #PCRX

0 0 0 0